Peptides DB
Research-centric peptide and protocol reference hub
Study 63 of 68HGH (Somatropin) literatureOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · Meta-analysis2026

Interaction between vitamin D and the growth hormone/insulin-like growth factor 1 axis in children: a systematic review and meta-analysis.

Vitamin D supplementation may increase IGF-1 levels in children, particularly when combined with rhGH therapy, but the clinical implications of these findings require careful consideration.

Read at Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAAdd to compare

Where it sits

this study against the rest of the hgh (somatropin) corpus
4
Preclinical
47
Observational
0
Open-label
10
Randomised
7
Reviews · this one

Summary and findings

This systematic review and meta-analysis evaluated the relationship between vitamin D and the growth hormone/insulin-like growth factor 1 axis in children. The study found that vitamin D supplementation increased IGF-1 levels and that vitamin D combined with recombinant human growth hormone (rhGH) therapy resulted in higher IGF-1 levels compared to rhGH alone. The meta-analysis included 24 studies with various findings on vitamin D levels in children with growth hormone deficiency and idiopathic short stature.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
WMD: 5.83 ng/mL increase in vitamin D levels after rhGH treatment, 95% CI: 3.72 to 7.94, p<0.00001.2026

Abstract

The authors’ words, as Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA supplied them

<h4>Background</h4>This article presents a systematic review and meta-analysis of relevant studies to clarify the relationship between vitamin D and the growth hormone/insulin-like growth factor 1(GH/IGF-1) axis.<h4>Methods</h4>PubMed/MEDLINE, Web of Science, SCOPUS, Embase, and CNKI databases were searched. Relevant articles on the effect of vitamin D on IGF-1 levels were reviewed. The effect of recombinant human growth hormone supplementation on 25-hydroxyvitamin D[25(OH)D] levels was meta-analyzed, and subgroup analyses were conducted.<h4>Results</h4>IGF-1 levels increased after vitamin D supplementation. Vitamin D combined with rhGH therapy resulted in higher IGF-1 levels than rhGH alone. The meta-analysis included 24 studies. Vitamin D levels increased after rhGH treatment (WMD: 5.83 ng/mL, 95% CI: 3.72 to 7.94, I² = 99%, p < 0.00001), both in children with GHD (WMD: 7.78 ng/mL, 95% CI: 2.02 to 13.55, I² = 99%, p = 0.008) and ISS(WMD: 2.74 ng/mL, 95% CI: 1.25 to 4.23, I² = 98%, p = 0.0003). Results showed that vitamin D levels in children with growth hormone deficiency (GHD) were significantly lower than those in healthy children (WMD: -8.69 ng/mL, 95% CI: -15.91 to -1.46, I² = 96%, p = 0.02). There was no significant difference in vitamin D levels between children with idiopathic short stature (ISS) and healthy children (WMD: -3.86 ng/mL, 95% CI: -7.70 to -0.01, I² = 98%, p = 0.05). However, vitamin D levels in short children remained lower than those in healthy children after rhGH treatment (WMD: -1.68 ng/mL, 95% CI: -2.53 to -0.82, I² = 84%, p = 0.0001).<h4>Conclusion</h4>The increase in IGF-1 levels following vitamin D supplementation should be accounted for in clinical practice when evaluating IGF-1 values to optimize the diagnosis of short stature causes. Children with GHD have lower vitamin D levels, and rhGH supplementation can increase vitamin D levels. Combined vitamin D and rhGH therapy can better promote growth and development in children with short stature.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the HGH (Somatropin) corpus

DAdvances in Systemic Treatment of Breast Cancer.The New England journal of medicine · 2026reviewBConverging Growth Trajectories During Recombinant Human Growth Hormone Therapy in Children With Isolated and Combined Pituitary Hormone Deficiency.Clinical endocrinology · 2023 · n=120 · Cumulative height SDS gains after 48 months: 3.10 ± 1.36 for CPHD vs. 1.92 ± 0.87 for IGHD, p < 0.001.HumanBMicrostructural Vulnerability of the Tibial Tubercle Apophysis During Growth Hormone Therapy: A Multicenter Prospective Cohort Study Using Diffusion Tensor Imaging-MRI.The Journal of bone and joint surgery. American volume · 2023 · n=53 · ADC was significantly higher at 8 months compared with baseline (1.61 × 10-3 vs 1.52 × 10-3 mm2/sec, p = 0.041).HumanBA Novel ACAN Missense Variant in the G1 Domain Causes Short Stature, Advanced Bone Age, and Osteochondritis Dissecans: A Case Report and Literature Review.Clinical genetics · 2023 · n=1 · Not reported in abstract.HumanAInteraction between vitamin D and the growth hormone/insulin-like growth factor 1 axis in children: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026 · WMD: 5.83 ng/mL increase in vitamin D levels after rhGH treatment, 95% CI: 3.72 to 7.94, p<0.00001.reviewBA Novel ACAN Missense Variant in the G1 Domain Causes Short Stature, Advanced Bone Age, and Osteochondritis Dissecans: A Case Report and Literature Review.Clinical genetics · 2026 · Not reported in abstract.Human